A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci136 for Injection in Healthy Adult Participants in China.
Latest Information Update: 03 Feb 2026
At a glance
- Drugs GenSci 136 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 03 Feb 2026 New trial record